NETAG reappraises bevacizumab (Avastin®) for diabetic macular oedema following appeal

Source: NETAG
Area: Evidence > Drug Specific Reviews
The NHS North East Treatment Advisory Group (NETAG) was requested to re-appraise bevacizumab (Avastin®) for the treatment of diabetic macular oedema in light of NICE not having recommended ranibizumab (Lucentis®) for the same indication. The group considered the evidence of the previous appraisal which included bevacizumab for DMO (October 2010) and was disappointed that the additional clinical evidence was of a similar low methodological quality. In addition, it noted substantial variations in the evaluated treatment and monitoring regimens and a general paucity (Read more...)

Full Story →